Trial Outcomes & Findings for A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People (NCT NCT05580003)

Results Overview

An adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

94 participants

Primary outcome timeframe

From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 48 days)

Results posted on

2024-11-21

Participant Flow

A total of 94 participants were enrolled across Belgium and United States.

Participant milestones

Participant milestones
Measure	P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast In this cohort (C), participants received a single dose of placebo as an oral suspension in the fasted (fast) state on Day 1 of Period 1 followed by a single dose of PF-07817883 1500 milligram (mg) as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of PF-07817883 4000 mg as an oral suspension in the fasted state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.	P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast Participants received a single dose of PF-07817883 150 mg as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of placebo as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of PF-07817883 4000 mg as an oral suspension in the fasted state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.	P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast Participants received a single dose of PF-07817883 150 mg as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of PF-07817883 1500 mg as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of placebo as an oral suspension in the fasted state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.	P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast Participants received a single dose of PF-07817883 150 mg as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of PF-07817883 1500 mg as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of PF-07817883 4000 mg as an oral suspension in the fasted state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.	P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed Participants received a single dose of placebo as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of PF-07817883 3000 mg as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of placebo as an oral suspension in the fed state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.	P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed Participants received a single dose of PF-07817883 500 mg as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of placebo as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of PF-07817883 500 mg as an oral suspension in the fed state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.	P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed Participants received a single dose of PF-07817883 500 mg as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of PF-07817883 3000 mg as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of PF-07817883 500 mg as an oral suspension in the fed state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.	Part 2: Placebo (Suspension) BID, Fasted Participants received placebo oral suspension twice a day (BID) administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of placebo in the morning under fasted conditions.	Part 2: PF-07817883 200 mg (Suspension) BID, Fasted Participants received PF-07817883 200 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 200 mg in the morning under fasted conditions.	Part 2: PF-07817883 600 mg (Suspension) BID, Fasted Participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.	Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted Participants received PF-07817883 1500 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 1500 mg in the morning under fasted conditions.	Part 2: Placebo (Suspension) BID, Fasted, Chinese Chinese participants received placebo oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of placebo in the morning under fasted conditions.	Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese Chinese participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.	Part 3: Treatment Sequence ABCD Participants received treatments A, B, C and D in Period 1, 2, 3 and 4 respectively. Treatment A: Single dose of PF-07817883 spray dried dispersion (SDD) 600 mg tablets in fasted conditions. Treatment B: Single dose of PF-07817883 crystalline 600 mg tablet in fasted conditions. Treatment C: Single dose of PF-07817883 600 mg suspension in fasted conditions. Treatment D: Single dose of PF-07817883 SDD 600 mg tablet in fed conditions. There was a washout of at least 3 days between 2 doses.	Part 3: Treatment Sequence BCAD Participants received treatments B, C, A and D in Period 1, 2, 3 and 4 respectively. Treatment B: Single dose of PF-07817883 crystalline 600 mg tablet in fasted conditions. Treatment C: Single dose of PF-07817883 600 mg suspension in fasted conditions. Treatment A: Single dose of PF-07817883 SDD 600 mg tablets in fasted conditions. Treatment D: Single dose of PF-07817883 SDD 600 mg tablet in fed conditions. There was a washout of at least 3 days between 2 doses.	Part 3: Treatment Sequence CABD Participants received treatments C, A, B and D in Period 1, 2, 3 and 4 respectively. Treatment C: Single dose of PF-07817883 600 mg suspension in fasted conditions. Treatment A: Single dose of PF-07817883 SDD 600 mg tablets in fasted conditions. Treatment B: Single dose of PF-07817883 crystalline 600 mg tablet in fasted conditions. Treatment D: Single dose of PF-07817883 SDD 600 mg tablet in fed conditions. There was a washout of at least 3 days between 2 doses.	Part 3: Treatment Sequence BACE Participants received treatments B, A, C and E in Period 1, 2, 3 and 4 respectively. Treatment B: Single dose of PF-07817883 crystalline 600 mg tablet in fasted conditions. Treatment A: Single dose of PF-07817883 SDD 600 mg tablets in fasted conditions. Treatment C: Single dose of PF-07817883 600 mg suspension in fasted conditions. Treatment E: Single dose of PF-07817883 crystalline 600 mg tablet in fed conditions. There was a washout of at least 3 days between 2 doses.	Part 3: Treatment Sequence ACBE Participants received treatments A, C, B and E in Period 1, 2, 3 and 4 respectively. Treatment A: Single dose of PF-07817883 SDD 600 mg tablets in fasted conditions. Treatment C: Single dose of PF-07817883 600 mg suspension in fasted conditions. Treatment B: Single dose of PF-07817883 crystalline 600 mg tablet in fasted conditions. Treatment E: Single dose of PF-07817883 crystalline 600 mg tablet in fed conditions. There was a washout of at least 3 days between 2 doses.	Part 3: Treatment Sequence CBAE Participants received treatments C, B, A and E in Period 1, 2, 3 and 4 respectively. Treatment C: Single dose of PF-07817883 600 mg suspension in fasted conditions. Treatment B: Single dose of PF-07817883 crystalline 600 mg tablet in fasted conditions. Treatment A: Single dose of PF-07817883 SDD 600 mg tablets in fasted conditions. Treatment E: Single dose of PF-07817883 crystalline 600 mg tablet in fed conditions. There was a washout of at least 3 days between 2 doses.	Part 4: PF-07817883 600 mg (Suspension), Fasted Participants received a single dose of PF-07817883 600 mg oral suspension on Day 1 following an overnight fast of approximately 10 hours.	Part 5: Treatment Sequence AB Participants received a single dose of midazolam 5 mg orally on Day 1 of Period 1 followed by a 2-day washout period. In Period 2, participants received PF-07817883 BID orally for 10 days followed by single dose of midazolam 5 mg on Day 10 followed by a washout of at least 7 days.	Part 5: Treatment Sequence BA In Period 1, participants received PF-07817883 BID orally for 10 days and on Day 10, participants received a single oral dose of 5 mg midazolam administered with PF-07817883 followed by a washout of at least 7 days. In Period 2, participants received a single dose of midazolam 5 mg orally followed by a 2-day washout period.	Part 6: Treatment Sequence ABC Participants received treatment A, B and C in Period 1, 2 and 3 respectively. Treatment A: PF-07817883 6000 mg oral suspension administered as 2 split doses of 3000 mg at 0 and 1 hour under fasted conditions. Treatment B: Single dose of Placebo oral suspension following an overnight fast of at least 10 hours. Treatment C: Single dose of Moxifloxacin 400 mg oral tablet at 0 hour and placebo at 1 hour following an overnight fast of at least 10 hours. Each period was separated by a washout of at least 7 days.	Part 6: Treatment Sequence BCA Participants received treatment B, C and A in Period 1, 2 and 3 respectively. Treatment B: Single dose of Placebo oral suspension following an overnight fast of at least 10 hours. Treatment C: Single dose of Moxifloxacin 400 mg oral tablet at 0 hour and placebo at 1 hour following an overnight fast of at least 10 hours. Treatment A: PF-07817883 6000 mg oral suspension administered as 2 split doses of 3000 mg at 0 and 1 hour under fasted conditions. Each period was separated by a washout of at least 7 days.	Part 6: Treatment Sequence CAB Participants received treatment C, A and B in Period 1, 2 and 3 respectively. Treatment C: Single dose of Moxifloxacin 400 mg oral tablet at 0 hour and placebo at 1 hour following an overnight fast of at least 10 hours. Treatment A: PF-07817883 6000 mg oral suspension administered as 2 split doses of 3000 mg at 0 and 1 hour under fasted conditions. Treatment B: Single dose of Placebo oral suspension following an overnight fast of at least 10 hours. Each period was separated by a washout of at least 7 days.	Part 6: Treatment Sequence BAC Participants received treatment B, A and C in Period 1, 2 and 3 respectively. Treatment B: Single dose of Placebo oral suspension following an overnight fast of at least 10 hours. Treatment A: PF-07817883 6000 mg oral suspension administered as 2 split doses of 3000 mg at 0 and 1 hour under fasted conditions. Treatment C: Single dose of Moxifloxacin 400 mg oral tablet at 0 hour and placebo at 1 hour following an overnight fast of at least 10 hours. Each period was separated by a washout of at least 7 days.	Part 6: Treatment Sequence ACB Participants received treatment A, C and B in Period 1, 2 and 3 respectively. Treatment A: PF-07817883 6000 mg oral suspension administered as 2 split doses of 3000 mg at 0 and 1 hour under fasted conditions. Treatment C: Single dose of Moxifloxacin 400 mg oral tablet at 0 hour and placebo at 1 hour following an overnight fast of at least 10 hours. Treatment B: Single dose of Placebo oral suspension following an overnight fast of at least 10 hours. Each period was separated by a washout of at least 7 days.	Part 6: Treatment Sequence CBA Participants received treatment C, B and A in Period 1, 2 and 3 respectively. Treatment C: Single dose of Moxifloxacin 400 mg oral tablet at 0 hour and placebo at 1 hour following an overnight fast of at least 10 hours. Treatment B: Single dose of Placebo oral suspension following an overnight fast of at least 10 hours. Treatment A: PF-07817883 6000 mg oral suspension administered as 2 split doses of 3000 mg at 0 and 1 hour under fasted conditions. Each period was separated by a washout of at least 7 days.
Part 5:SequenceAB:Washout1(Upto 2 Days) COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	0	0	0	0	0	0	0
Part (P) 1 Treatment Period 1 (Day 1) STARTED	2	2	2	2	2	2	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part (P) 1 Treatment Period 1 (Day 1) COMPLETED	2	2	2	2	2	2	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part (P) 1 Treatment Period 1 (Day 1) NOT COMPLETED	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 1: Washout 1 (up to 5 Days) STARTED	2	2	2	2	2	2	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 1: Washout 1 (up to 5 Days) COMPLETED	2	2	2	2	2	2	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 1: Washout 1 (up to 5 Days) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 1 Treatment Period 2 (Day 1) STARTED	2	2	2	2	2	2	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 1 Treatment Period 2 (Day 1) COMPLETED	2	2	2	1	2	1	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 1 Treatment Period 2 (Day 1) NOT COMPLETED	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 1: Washout 2 (up to 5 Days) STARTED	2	2	2	1	2	1	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 1: Washout 2 (up to 5 Days) COMPLETED	2	2	2	1	2	1	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 1: Washout 2 (up to 5 Days) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 1: Treatment Period 3 (Day 1) STARTED	2	2	2	1	2	1	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 1: Treatment Period 3 (Day 1) COMPLETED	2	1	2	1	2	1	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 1: Treatment Period 3 (Day 1) NOT COMPLETED	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 2 (up to 10 Days) STARTED	0	0	0	0	0	0	0	6	4	4	4	1	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 2 (up to 10 Days) COMPLETED	0	0	0	0	0	0	0	6	4	3	4	1	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 2 (up to 10 Days) NOT COMPLETED	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 3 Period 1 (Day 1) STARTED	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	2	2	2	2	0	0	0	0	0	0	0	0	0
Part 3 Period 1 (Day 1) COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	2	2	2	2	0	0	0	0	0	0	0	0	0
Part 3 Period 1 (Day 1) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 3: Washout 1 (up to 3 Days) STARTED	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	2	2	2	2	0	0	0	0	0	0	0	0	0
Part 3: Washout 1 (up to 3 Days) COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	2	2	2	2	0	0	0	0	0	0	0	0	0
Part 3: Washout 1 (up to 3 Days) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 3: Period 2 (Day 1) STARTED	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	2	2	2	2	0	0	0	0	0	0	0	0	0
Part 3: Period 2 (Day 1) COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	2	2	2	2	0	0	0	0	0	0	0	0	0
Part 3: Period 2 (Day 1) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 3: Washout 2 (up to 3 Days) STARTED	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	2	2	2	2	0	0	0	0	0	0	0	0	0
Part 3: Washout 2 (up to 3 Days) COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	2	2	2	2	0	0	0	0	0	0	0	0	0
Part 3: Washout 2 (up to 3 Days) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 3: Period 3 (Day 1) STARTED	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	2	2	2	2	0	0	0	0	0	0	0	0	0
Part 3: Period 3 (Day 1) COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	2	2	2	2	0	0	0	0	0	0	0	0	0
Part 3: Period 3 (Day 1) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 3: Washout 3 (up to 3 Days) STARTED	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	2	2	2	2	0	0	0	0	0	0	0	0	0
Part 3: Washout 3 (up to 3 Days) COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	2	2	2	2	0	0	0	0	0	0	0	0	0
Part 3: Washout 3 (up to 3 Days) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 3: Period 4 (Day 1) STARTED	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	2	2	2	2	0	0	0	0	0	0	0	0	0
Part 3: Period 4 (Day 1) COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	2	2	2	2	0	0	0	0	0	0	0	0	0
Part 3: Period 4 (Day 1) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 4 (Day 1 to Day 11) STARTED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	0	0	0	0	0	0	0	0
Part 4 (Day 1 to Day 11) COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	0	0	0	0	0	0	0	0
Part 4 (Day 1 to Day 11) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Part 5: Sequence AB: Period 1 (Day 1) STARTED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7	0	0	0	0	0	0	0
Part 5: Sequence AB: Period 1 (Day 1) COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	0	0	0	0	0	0	0
Part 5: Sequence AB: Period 1 (Day 1) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Part 5:SequenceAB:Washout1(Upto 2 Days) STARTED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	0	0	0	0	0	0	0
Part 5:SequenceAB:Washout1(Upto 2 Days) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part5:SequenceAB:Period2(up to 10 Days) STARTED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	0	0	0	0	0	0	0
Part5:SequenceAB:Period2(up to 10 Days) COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	0	0	0	0	0	0	0
Part5:SequenceAB:Period2(up to 10 Days) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part5:Sequence AB:Washout2(up to 7 Days) STARTED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	0	0	0	0	0	0	0
Part5:Sequence AB:Washout2(up to 7 Days) COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	0	0	0	0	0	0	0
Part5:Sequence AB:Washout2(up to 7 Days) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part5:Sequence BA:Period1(up to 10 Days) STARTED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7	0	0	0	0	0	0
Part5:Sequence BA:Period1(up to 10 Days) COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	0	0	0	0	0	0
Part5:Sequence BA:Period1(up to 10 Days) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Part5:Sequence BA:Washout1(up to 7 Days) STARTED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	0	0	0	0	0	0
Part5:Sequence BA:Washout1(up to 7 Days) COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	0	0	0	0	0	0
Part5:Sequence BA:Washout1(up to 7 Days) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 5: Sequence BA: Period 2 (Day 1) STARTED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	0	0	0	0	0	0
Part 5: Sequence BA: Period 2 (Day 1) COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	0	0	0	0	0	0
Part 5: Sequence BA: Period 2 (Day 1) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part5:Sequence BA:Washout2(up to 2 Days) STARTED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	0	0	0	0	0	0
Part5:Sequence BA:Washout2(up to 2 Days) COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	0	0	0	0	0	0
Part5:Sequence BA:Washout2(up to 2 Days) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 6 Period 1 (Day 1) STARTED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	4	4	4	4	4
Part 6 Period 1 (Day 1) COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	4	4	4	4	4
Part 6 Period 1 (Day 1) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 6: Washout 1 (up to 7 Days) STARTED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	4	4	4	4	4
Part 6: Washout 1 (up to 7 Days) COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	4	4	4	4	4
Part 6: Washout 1 (up to 7 Days) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 6 Period 2 (Day 1) STARTED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	4	4	4	4	4
Part 6 Period 2 (Day 1) COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	4	3	4	4	3
Part 6 Period 2 (Day 1) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1
Part 6: Washout 2 (up to 7 Days) STARTED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	4	3	4	4	3
Part 6: Washout 2 (up to 7 Days) COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	4	3	4	4	3
Part 6: Washout 2 (up to 7 Days) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 6 Period 3 (Day 1) STARTED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	4	3	4	4	3
Part 6 Period 3 (Day 1) COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	4	3	4	4	3
Part 6 Period 3 (Day 1) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Reasons for withdrawal

Reasons for withdrawal
Measure	P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast Participants received a single dose of PF-07817883 150 mg as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of placebo as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of PF-07817883 4000 mg as an oral suspension in the fasted state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.	P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast Participants received a single dose of PF-07817883 150 mg as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of PF-07817883 1500 mg as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of PF-07817883 4000 mg as an oral suspension in the fasted state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.	P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed Participants received a single dose of PF-07817883 500 mg as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of placebo as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of PF-07817883 500 mg as an oral suspension in the fed state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.	P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed Participants received a single dose of PF-07817883 500 mg as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of PF-07817883 3000 mg as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of PF-07817883 500 mg as an oral suspension in the fed state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.	Part 2: PF-07817883 600 mg (Suspension) BID, Fasted Participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.	Part 4: PF-07817883 600 mg (Suspension), Fasted Participants received a single dose of PF-07817883 600 mg oral suspension on Day 1 following an overnight fast of approximately 10 hours.	Part 5: Treatment Sequence AB Participants received a single dose of midazolam 5 mg orally on Day 1 of Period 1 followed by a 2-day washout period. In Period 2, participants received PF-07817883 BID orally for 10 days followed by single dose of midazolam 5 mg on Day 10 followed by a washout of at least 7 days.	Part 5: Treatment Sequence BA In Period 1, participants received PF-07817883 BID orally for 10 days and on Day 10, participants received a single oral dose of 5 mg midazolam administered with PF-07817883 followed by a washout of at least 7 days. In Period 2, participants received a single dose of midazolam 5 mg orally followed by a 2-day washout period.	Part 6: Treatment Sequence CAB Participants received treatment C, A and B in Period 1, 2 and 3 respectively. Treatment C: Single dose of Moxifloxacin 400 mg oral tablet at 0 hour and placebo at 1 hour following an overnight fast of at least 10 hours. Treatment A: PF-07817883 6000 mg oral suspension administered as 2 split doses of 3000 mg at 0 and 1 hour under fasted conditions. Treatment B: Single dose of Placebo oral suspension following an overnight fast of at least 10 hours. Each period was separated by a washout of at least 7 days.	Part 6: Treatment Sequence CBA Participants received treatment C, B and A in Period 1, 2 and 3 respectively. Treatment C: Single dose of Moxifloxacin 400 mg oral tablet at 0 hour and placebo at 1 hour following an overnight fast of at least 10 hours. Treatment B: Single dose of Placebo oral suspension following an overnight fast of at least 10 hours. Treatment A: PF-07817883 6000 mg oral suspension administered as 2 split doses of 3000 mg at 0 and 1 hour under fasted conditions. Each period was separated by a washout of at least 7 days.
Part (P) 1 Treatment Period 1 (Day 1) Withdrawal by Subject	0	0	0	1	0	0	0	0	0	0
Part 1 Treatment Period 2 (Day 1) Physician Decision	0	0	1	0	0	0	0	0	0	0
Part 1 Treatment Period 2 (Day 1) Other	0	1	0	0	0	0	0	0	0	0
Part 1: Treatment Period 3 (Day 1) Physician Decision	1	0	0	0	0	0	0	0	0	0
Part 2 (up to 10 Days) Other	0	0	0	0	1	0	0	0	0	0
Part 4 (Day 1 to Day 11) Adverse Event	0	0	0	0	0	1	0	0	0	0
Part 5: Sequence AB: Period 1 (Day 1) Adverse Event	0	0	0	0	0	0	1	0	0	0
Part5:Sequence BA:Period1(up to 10 Days) Adverse Event	0	0	0	0	0	0	0	1	0	0
Part 6 Period 2 (Day 1) Adverse Event	0	0	0	0	0	0	0	0	0	1
Part 6 Period 2 (Day 1) Other	0	0	0	0	0	0	0	0	1	0

Baseline Characteristics

A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast n=2 Participants In this cohort (C), participants received a single dose of placebo as an oral suspension in the fasted (fast) state on Day 1 of Period 1 followed by a single dose of PF-07817883 1500 milligram (mg) as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of PF-07817883 4000 mg as an oral suspension in the fasted state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.	P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast n=2 Participants Participants received a single dose of PF-07817883 150 mg as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of placebo as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of PF-07817883 4000 mg as an oral suspension in the fasted state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.	P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast n=2 Participants Participants received a single dose of PF-07817883 150 mg as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of PF-07817883 1500 mg as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of placebo as an oral suspension in the fasted state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.	P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast n=2 Participants Participants received a single dose of PF-07817883 150 mg as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of PF-07817883 1500 mg as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of PF-07817883 4000 mg as an oral suspension in the fasted state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.	P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed n=2 Participants Participants received a single dose of placebo as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of PF-07817883 3000 mg as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of placebo as an oral suspension in the fed state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.	P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed n=2 Participants Participants received a single dose of PF-07817883 500 mg as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of placebo as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of PF-07817883 500 mg as an oral suspension in the fed state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.	P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed n=4 Participants Participants received a single dose of PF-07817883 500 mg as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of PF-07817883 3000 mg as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of PF-07817883 500 mg as an oral suspension in the fed state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.	Part 2: Placebo (Suspension) BID, Fasted n=6 Participants Participants received placebo oral suspension twice a day (BID) administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of placebo in the morning under fasted conditions.	Part 2: PF-07817883 200 mg (Suspension) BID, Fasted n=4 Participants Participants received PF-07817883 200 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 200 mg in the morning under fasted conditions.	Part 2: PF-07817883 600 mg (Suspension) BID, Fasted n=4 Participants Participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.	Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted n=4 Participants Participants received PF-07817883 1500 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 1500 mg in the morning under fasted conditions.	Part 2: Placebo (Suspension) BID, Fasted, Chinese n=1 Participants Chinese participants received placebo oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of placebo in the morning under fasted conditions.	Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese n=3 Participants Chinese participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.	Part 3: Treatment Sequence ABCD n=2 Participants Participants received treatments A, B, C and D in Period 1, 2, 3 and 4 respectively. Treatment A: Single dose of PF-07817883 spray dried dispersion (SDD) 600 mg tablets in fasted conditions. Treatment B: Single dose of PF-07817883 crystalline 600 mg tablet in fasted conditions. Treatment C: Single dose of PF-07817883 600 mg suspension in fasted conditions. Treatment D: Single dose of PF-07817883 SDD 600 mg tablet in fed conditions. There was a washout of at least 3 days between 2 doses.	Part 3: Treatment Sequence BCAD n=2 Participants Participants received treatments B, C, A and D in Period 1, 2, 3 and 4 respectively. Treatment B: Single dose of PF-07817883 crystalline 600 mg tablet in fasted conditions. Treatment C: Single dose of PF-07817883 600 mg suspension in fasted conditions. Treatment A: Single dose of PF-07817883 SDD 600 mg tablets in fasted conditions. Treatment D: Single dose of PF-07817883 SDD 600 mg tablet in fed conditions. There was a washout of at least 3 days between 2 doses.	Part 3: Treatment Sequence CABD n=2 Participants Participants received treatments C, A, B and D in Period 1, 2, 3 and 4 respectively. Treatment C: Single dose of PF-07817883 600 mg suspension in fasted conditions. Treatment A: Single dose of PF-07817883 SDD 600 mg tablets in fasted conditions. Treatment B: Single dose of PF-07817883 crystalline 600 mg tablet in fasted conditions. Treatment D: Single dose of PF-07817883 SDD 600 mg tablet in fed conditions. There was a washout of at least 3 days between 2 doses.	Part 3: Treatment Sequence BACE n=2 Participants Participants received treatments B, A, C and E in Period 1, 2, 3 and 4 respectively. Treatment B: Single dose of PF-07817883 crystalline 600 mg tablet in fasted conditions. Treatment A: Single dose of PF-07817883 SDD 600 mg tablets in fasted conditions. Treatment C: Single dose of PF-07817883 600 mg suspension in fasted conditions. Treatment E: Single dose of PF-07817883 crystalline 600 mg tablet in fed conditions. There was a washout of at least 3 days between 2 doses.	Part 3: Treatment Sequence ACBE n=2 Participants Participants received treatments A, C, B and E in Period 1, 2, 3 and 4 respectively. Treatment A: Single dose of PF-07817883 SDD 600 mg tablets in fasted conditions. Treatment C: Single dose of PF-07817883 600 mg suspension in fasted conditions. Treatment B: Single dose of PF-07817883 crystalline 600 mg tablet in fasted conditions. Treatment E: Single dose of PF-07817883 crystalline 600 mg tablet in fed conditions. There was a washout of at least 3 days between 2 doses.	Part 3: Treatment Sequence CBAE n=2 Participants Participants received treatments C, B, A and E in Period 1, 2, 3 and 4 respectively. Treatment C: Single dose of PF-07817883 600 mg suspension in fasted conditions. Treatment B: Single dose of PF-07817883 crystalline 600 mg tablet in fasted conditions. Treatment A: Single dose of PF-07817883 SDD 600 mg tablets in fasted conditions. Treatment E: Single dose of PF-07817883 crystalline 600 mg tablet in fed conditions. There was a washout of at least 3 days between 2 doses.	Part 4: PF-07817883 600 mg (Suspension), Fasted n=6 Participants Participants received a single dose of PF-07817883 600 mg oral suspension on Day 1 following an overnight fast of approximately 10 hours.	Part 5: Treatment Sequence AB n=7 Participants Participants received a single dose of midazolam 5 mg orally on Day 1 of Period 1 followed by a 2-day washout period. In Period 2, participants received PF-07817883 BID orally for 10 days followed by single dose of midazolam 5 mg on Day 10 followed by a washout of at least 7 days.	Part 5: Treatment Sequence BA n=7 Participants In Period 1, participants received PF-07817883 BID orally for 10 days and on Day 10, participants received a single oral dose of 5 mg midazolam administered with PF-07817883 followed by a washout of at least 7 days. In Period 2, participants received a single dose of midazolam 5 mg orally followed by a 2-day washout period.	Part 6: Treatment Sequence ABC n=4 Participants Participants received treatment A, B and C in Period 1, 2 and 3 respectively. Treatment A: PF-07817883 6000 mg oral suspension administered as 2 split doses of 3000 mg at 0 and 1 hour under fasted conditions. Treatment B: Single dose of Placebo oral suspension following an overnight fast of at least 10 hours. Treatment C: Single dose of Moxifloxacin 400 mg oral tablet at 0 hour and placebo at 1 hour following an overnight fast of at least 10 hours. Each period was separated by a washout of at least 7 days.	Part 6: Treatment Sequence BCA n=4 Participants Participants received treatment B, C and A in Period 1, 2 and 3 respectively. Treatment B: Single dose of Placebo oral suspension following an overnight fast of at least 10 hours. Treatment C: Single dose of Moxifloxacin 400 mg oral tablet at 0 hour and placebo at 1 hour following an overnight fast of at least 10 hours. Treatment A: PF-07817883 6000 mg oral suspension administered as 2 split doses of 3000 mg at 0 and 1 hour under fasted conditions. Each period was separated by a washout of at least 7 days.	Part 6: Treatment Sequence CAB n=4 Participants Participants received treatment C, A and B in Period 1, 2 and 3 respectively. Treatment C: Single dose of Moxifloxacin 400 mg oral tablet at 0 hour and placebo at 1 hour following an overnight fast of at least 10 hours. Treatment A: PF-07817883 6000 mg oral suspension administered as 2 split doses of 3000 mg at 0 and 1 hour under fasted conditions. Treatment B: Single dose of Placebo oral suspension following an overnight fast of at least 10 hours. Each period was separated by a washout of at least 7 days.	Part 6: Treatment Sequence BAC n=4 Participants Participants received treatment B, A and C in Period 1, 2 and 3 respectively. Treatment B: Single dose of Placebo oral suspension following an overnight fast of at least 10 hours. Treatment A: PF-07817883 6000 mg oral suspension administered as 2 split doses of 3000 mg at 0 and 1 hour under fasted conditions. Treatment C: Single dose of Moxifloxacin 400 mg oral tablet at 0 hour and placebo at 1 hour following an overnight fast of at least 10 hours. Each period was separated by a washout of at least 7 days.	Part 6: Treatment Sequence ACB n=4 Participants Participants received treatment A, C and B in Period 1, 2 and 3 respectively. Treatment A: PF-07817883 6000 mg oral suspension administered as 2 split doses of 3000 mg at 0 and 1 hour under fasted conditions. Treatment C: Single dose of Moxifloxacin 400 mg oral tablet at 0 hour and placebo at 1 hour following an overnight fast of at least 10 hours. Treatment B: Single dose of Placebo oral suspension following an overnight fast of at least 10 hours. Each period was separated by a washout of at least 7 days.	Part 6: Treatment Sequence CBA n=4 Participants Participants received treatment C, B and A in Period 1, 2 and 3 respectively. Treatment C: Single dose of Moxifloxacin 400 mg oral tablet at 0 hour and placebo at 1 hour following an overnight fast of at least 10 hours. Treatment B: Single dose of Placebo oral suspension following an overnight fast of at least 10 hours. Treatment A: PF-07817883 6000 mg oral suspension administered as 2 split doses of 3000 mg at 0 and 1 hour under fasted conditions. Each period was separated by a washout of at least 7 days.	Total n=94 Participants Total of all reporting groups
Age, Customized 18-44 Years	0 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants	2 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=8 Participants	2 Participants n=8 Participants	5 Participants n=24 Participants	2 Participants n=42 Participants	4 Participants n=42 Participants	2 Participants n=42 Participants	0 Participants n=42 Participants	3 Participants n=36 Participants	2 Participants n=36 Participants	0 Participants n=24 Participants	1 Participants n=135 Participants	1 Participants n=136 Participants	2 Participants n=44 Participants	2 Participants n=667 Participants	4 Participants n=12 Participants	4 Participants n=12 Participants	3 Participants n=12 Participants	3 Participants n=12 Participants	4 Participants n=11 Participants	4 Participants n=6 Participants	3 Participants n=7 Participants	3 Participants n=7 Participants	4 Participants n=408 Participants	64 Participants n=206 Participants
Age, Customized 45-60 Years	2 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=8 Participants	2 Participants n=8 Participants	1 Participants n=24 Participants	2 Participants n=42 Participants	0 Participants n=42 Participants	2 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=36 Participants	0 Participants n=36 Participants	2 Participants n=24 Participants	1 Participants n=135 Participants	1 Participants n=136 Participants	0 Participants n=44 Participants	0 Participants n=667 Participants	2 Participants n=12 Participants	3 Participants n=12 Participants	4 Participants n=12 Participants	1 Participants n=12 Participants	0 Participants n=11 Participants	0 Participants n=6 Participants	1 Participants n=7 Participants	1 Participants n=7 Participants	0 Participants n=408 Participants	29 Participants n=206 Participants
Age, Customized Not Disclosed	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants	0 Participants n=36 Participants	0 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	0 Participants n=136 Participants	0 Participants n=44 Participants	0 Participants n=667 Participants	0 Participants n=12 Participants	0 Participants n=12 Participants	0 Participants n=12 Participants	0 Participants n=12 Participants	0 Participants n=11 Participants	0 Participants n=6 Participants	0 Participants n=7 Participants	0 Participants n=7 Participants	0 Participants n=408 Participants	1 Participants n=206 Participants
Sex/Gender, Customized Female	1 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=8 Participants	1 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	2 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=36 Participants	1 Participants n=36 Participants	0 Participants n=24 Participants	2 Participants n=135 Participants	1 Participants n=136 Participants	2 Participants n=44 Participants	0 Participants n=667 Participants	0 Participants n=12 Participants	2 Participants n=12 Participants	2 Participants n=12 Participants	0 Participants n=12 Participants	1 Participants n=11 Participants	1 Participants n=6 Participants	1 Participants n=7 Participants	0 Participants n=7 Participants	0 Participants n=408 Participants	19 Participants n=206 Participants
Sex/Gender, Customized Male	1 Participants n=5 Participants	2 Participants n=7 Participants	1 Participants n=5 Participants	2 Participants n=4 Participants	1 Participants n=21 Participants	2 Participants n=8 Participants	3 Participants n=8 Participants	6 Participants n=24 Participants	4 Participants n=42 Participants	2 Participants n=42 Participants	4 Participants n=42 Participants	0 Participants n=42 Participants	3 Participants n=36 Participants	1 Participants n=36 Participants	2 Participants n=24 Participants	0 Participants n=135 Participants	1 Participants n=136 Participants	0 Participants n=44 Participants	2 Participants n=667 Participants	6 Participants n=12 Participants	5 Participants n=12 Participants	5 Participants n=12 Participants	4 Participants n=12 Participants	3 Participants n=11 Participants	3 Participants n=6 Participants	3 Participants n=7 Participants	4 Participants n=7 Participants	4 Participants n=408 Participants	74 Participants n=206 Participants
Sex/Gender, Customized Not Disclosed	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants	0 Participants n=36 Participants	0 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	0 Participants n=136 Participants	0 Participants n=44 Participants	0 Participants n=667 Participants	0 Participants n=12 Participants	0 Participants n=12 Participants	0 Participants n=12 Participants	0 Participants n=12 Participants	0 Participants n=11 Participants	0 Participants n=6 Participants	0 Participants n=7 Participants	0 Participants n=7 Participants	0 Participants n=408 Participants	1 Participants n=206 Participants
Race/Ethnicity, Customized American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=36 Participants	0 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	0 Participants n=136 Participants	0 Participants n=44 Participants	0 Participants n=667 Participants	0 Participants n=12 Participants	0 Participants n=12 Participants	0 Participants n=12 Participants	0 Participants n=12 Participants	1 Participants n=11 Participants	0 Participants n=6 Participants	0 Participants n=7 Participants	0 Participants n=7 Participants	0 Participants n=408 Participants	2 Participants n=206 Participants
Race/Ethnicity, Customized Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants	2 Participants n=42 Participants	0 Participants n=42 Participants	3 Participants n=36 Participants	0 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	1 Participants n=136 Participants	1 Participants n=44 Participants	0 Participants n=667 Participants	1 Participants n=12 Participants	2 Participants n=12 Participants	4 Participants n=12 Participants	1 Participants n=12 Participants	0 Participants n=11 Participants	1 Participants n=6 Participants	0 Participants n=7 Participants	1 Participants n=7 Participants	1 Participants n=408 Participants	19 Participants n=206 Participants
Race/Ethnicity, Customized Black or African American	1 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=8 Participants	2 Participants n=8 Participants	1 Participants n=24 Participants	3 Participants n=42 Participants	2 Participants n=42 Participants	1 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=36 Participants	1 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	1 Participants n=136 Participants	1 Participants n=44 Participants	1 Participants n=667 Participants	1 Participants n=12 Participants	2 Participants n=12 Participants	1 Participants n=12 Participants	2 Participants n=12 Participants	1 Participants n=11 Participants	1 Participants n=6 Participants	3 Participants n=7 Participants	0 Participants n=7 Participants	1 Participants n=408 Participants	31 Participants n=206 Participants
Race/Ethnicity, Customized White	1 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=8 Participants	2 Participants n=8 Participants	4 Participants n=24 Participants	1 Participants n=42 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=36 Participants	1 Participants n=36 Participants	2 Participants n=24 Participants	2 Participants n=135 Participants	0 Participants n=136 Participants	0 Participants n=44 Participants	1 Participants n=667 Participants	3 Participants n=12 Participants	3 Participants n=12 Participants	2 Participants n=12 Participants	1 Participants n=12 Participants	2 Participants n=11 Participants	2 Participants n=6 Participants	1 Participants n=7 Participants	3 Participants n=7 Participants	2 Participants n=408 Participants	39 Participants n=206 Participants
Race/Ethnicity, Customized More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	1 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=36 Participants	0 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	0 Participants n=136 Participants	0 Participants n=44 Participants	0 Participants n=667 Participants	1 Participants n=12 Participants	0 Participants n=12 Participants	0 Participants n=12 Participants	0 Participants n=12 Participants	0 Participants n=11 Participants	0 Participants n=6 Participants	0 Participants n=7 Participants	0 Participants n=7 Participants	0 Participants n=408 Participants	2 Participants n=206 Participants
Race/Ethnicity, Customized Not Disclosed	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants	0 Participants n=36 Participants	0 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	0 Participants n=136 Participants	0 Participants n=44 Participants	0 Participants n=667 Participants	0 Participants n=12 Participants	0 Participants n=12 Participants	0 Participants n=12 Participants	0 Participants n=12 Participants	0 Participants n=11 Participants	0 Participants n=6 Participants	0 Participants n=7 Participants	0 Participants n=7 Participants	0 Participants n=408 Participants	1 Participants n=206 Participants
Race/Ethnicity, Customized Hispanic or Latino	1 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants	2 Participants n=21 Participants	1 Participants n=8 Participants	1 Participants n=8 Participants	4 Participants n=24 Participants	2 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=36 Participants	0 Participants n=36 Participants	0 Participants n=24 Participants	2 Participants n=135 Participants	1 Participants n=136 Participants	0 Participants n=44 Participants	0 Participants n=667 Participants	1 Participants n=12 Participants	3 Participants n=12 Participants	1 Participants n=12 Participants	0 Participants n=12 Participants	3 Participants n=11 Participants	2 Participants n=6 Participants	2 Participants n=7 Participants	2 Participants n=7 Participants	2 Participants n=408 Participants	33 Participants n=206 Participants
Race/Ethnicity, Customized Not Hispanic or Latino	1 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants	3 Participants n=8 Participants	2 Participants n=24 Participants	2 Participants n=42 Participants	4 Participants n=42 Participants	4 Participants n=42 Participants	0 Participants n=42 Participants	3 Participants n=36 Participants	2 Participants n=36 Participants	2 Participants n=24 Participants	0 Participants n=135 Participants	1 Participants n=136 Participants	2 Participants n=44 Participants	2 Participants n=667 Participants	5 Participants n=12 Participants	4 Participants n=12 Participants	6 Participants n=12 Participants	4 Participants n=12 Participants	1 Participants n=11 Participants	2 Participants n=6 Participants	2 Participants n=7 Participants	2 Participants n=7 Participants	2 Participants n=408 Participants	60 Participants n=206 Participants

PRIMARY outcome

Timeframe: From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 48 days)

Population: Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.

An adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=10 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=2 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)	3 Participants	4 Participants	1 Participants	2 Participants	1 Participants	0 Participants	0 Participants	1 Participants

PRIMARY outcome

Timeframe: From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 48 days)

Population: Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.

Laboratory parameters included: (lymphocytes less than (\<) 0.8\*lower limit of normal \[LLN\] \[10\^3 per millimeter cube {mm3}\], lymphocytes/leukocytes \<0.8\*LLN \[percentage {%}\], neutrophils \<0.8\*LLN \[10\^3/mm3\], neutrophils/leukocytes \<0.8\*LLN \[%\], monocytes/leukocytes greater than (\>) 1.2\*upper limit of normal \[ULN\] \[%\], partial thromboplastin time \>1.1\*ULN \[seconds\]), chemistry (bicarbonate \<0.9\*LLN \[milliequivalents per liter {mEq/L}\], creatine kinase \>2.0\*ULN \[units per liter {U/L}\], lipase \>1.5\*ULN \[U/L\]), and urinalysis (urine hemoglobin greater than or equal to \[\>=\] 1, leukocyte esterase \>=1). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=10 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=2 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 1: Number of Participants With Laboratory Test Abnormalities	1 Participants	5 Participants	1 Participants	2 Participants	2 Participants	1 Participants	2 Participants	2 Participants

PRIMARY outcome

Timeframe: Up to Day 2 of each period

Population: Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.

Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR) were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value less than (\<) 90 millimeter of mercury (mmHg), change greater than or equal to (\>=) 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 beats per minute (bpm), value \> 120 bpm.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=10 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=2 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 1: Number of Participants With Vital Signs Meeting Pre-Defined Criteria DBP Change >= 20 mmHg increase	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Vital Signs Meeting Pre-Defined Criteria DBP Change >= 20 mmHg decrease	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Vital Signs Meeting Pre-Defined Criteria SBP value < 90 mmHg	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants	1 Participants	0 Participants
Part 1: Number of Participants With Vital Signs Meeting Pre-Defined Criteria SBP Change >= 30 mmHg increase	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Vital Signs Meeting Pre-Defined Criteria SBP Change >= 30 mmHg decrease	0 Participants	0 Participants	0 Participants	2 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Vital Signs Meeting Pre-Defined Criteria DBP Value < 50 mmHg	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Vital Signs Meeting Pre-Defined Criteria PR Value < 40 bpm	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Vital Signs Meeting Pre-Defined Criteria PR Value > 120 bpm	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants

PRIMARY outcome

Timeframe: Up to Day 2 of each period

Population: Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.

Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=10 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=2 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 1: Number of Participants With Electrocardiogram (ECG) Abnormalities	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants

PRIMARY outcome

Timeframe: From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 55 days)

Population: Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.

An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted n=3 Participants Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=1 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)	2 Participants	2 Participants	1 Participants	0 Participants	2 Participants	0 Participants	—	—

PRIMARY outcome

Timeframe: From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 55 days)

Population: Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.

Laboratory parameters included: hematology (lymphocytes/leukocytes \>1.2\*ULN \[%\], neutrophils \<0.8\*LLN \[10\^3/mm3\], neutrophils/leukocytes \<0.8\*LLN \[%\], monocytes/leukocytes \>1.2\*ULN \[%\]), chemistry (urate \>1.2\*ULN \[milligrams per deciliter\] {mg/dL}), and urinalysis (ketones \>=1, urine hemoglobin \>=1). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted n=3 Participants Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=1 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 2: Number of Participants With Laboratory Test Abnormalities	1 Participants	1 Participants	2 Participants	2 Participants	2 Participants	0 Participants	—	—

PRIMARY outcome

Timeframe: Up to Day 12

Population: Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.

Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 bpm, value \> 120 bpm. 4. Number of participants with vital signs meeting any of the pre-defined criteria is reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted n=3 Participants Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=1 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 2: Number of Participants With Vital Signs Meeting Pre-Defined Criteria	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—

PRIMARY outcome

Timeframe: Up to Day 12

Population: Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.

Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted n=3 Participants Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=1 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 2: Number of Participants With Electrocardiogram (ECG) Abnormalities	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—

PRIMARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

Population: Pharmacokinetic (PK) parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number of Participants Analyzed'' signifies participants evaluable for this outcome measure.

Data for AUClast and AUCinf are reported in the descriptive section. AUClast was calculated by the linear/log trapezoidal method. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis. Ratio based on AUClast and AUCinf of oral formulation and suspension were reported in statistical analysis.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 3:Ratio Based on Area Under Plasma Concentration Time Curve From Time 0 to Time of Last Quantifiable Concentration (AUClast) and Area Under Concentration-Time Curve From Time 0 Extrapolated to Infinite Time (AUCinf) of Oral Formulation and Suspension AUCinf	—	42970 NanogramHour per milliliter (nghr/mL) Geometric Coefficient of Variation 35	44140 NanogramHour per milliliter (nghr/mL) Geometric Coefficient of Variation 38	28430 NanogramHour per milliliter (nghr/mL) Geometric Coefficient of Variation 28	42930 NanogramHour per milliliter (nghr/mL) Geometric Coefficient of Variation 43	46170 NanogramHour per milliliter (nghr/mL) Geometric Coefficient of Variation 27	—	—
Part 3:Ratio Based on Area Under Plasma Concentration Time Curve From Time 0 to Time of Last Quantifiable Concentration (AUClast) and Area Under Concentration-Time Curve From Time 0 Extrapolated to Infinite Time (AUCinf) of Oral Formulation and Suspension AUClast	—	42540 NanogramHour per milliliter (nghr/mL) Geometric Coefficient of Variation 35	43570 NanogramHour per milliliter (nghr/mL) Geometric Coefficient of Variation 37	27750 NanogramHour per milliliter (nghr/mL) Geometric Coefficient of Variation 29	41620 NanogramHour per milliliter (nghr/mL) Geometric Coefficient of Variation 41	35930 NanogramHour per milliliter (nghr/mL) Geometric Coefficient of Variation 54	—	—

PRIMARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported.

Data for Cmax are reported in the descriptive section. Ratio based on Cmax of oral formulation and suspension were reported in statistical analysis.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 3: Ratio Based on Maximum Observed Concentration (Cmax) of Oral Formulation and Suspension	—	9354 Nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 18	6934 Nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 35	4590 Nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 21	6284 Nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 38	5008 Nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 47	—	—

PRIMARY outcome

Timeframe: Up to 144 hours post-dose

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number of Participants Analyzed'' signifies participants evaluable for this outcome measure.

The percentage of total dose administered recovered in urine was reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 4: Percentage of Total Dose Administered Recovered in Urine	—	12.6 Percentage dose excreted Standard Deviation 4.7	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Up to 144 hours post-dose

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number of Participants Analyzed'' signifies participants evaluable for this outcome measure.

The percentage of total dose administered recovered in feces was reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 4: Percentage of Total Dose Administered Recovered in Feces	—	88.9 Percentage dose excreted Standard Deviation 10	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Up to 144 hours post-dose

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number of Participants Analyzed'' signifies participants evaluable for this outcome measure.

The percentage of total dose administered recovered in urine and feces was reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 4: Percentage of Total Dose Administered Recovered in Urine and Feces	—	101.5 Percentage dose excreted Standard Deviation 7.7	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number of Participants Analyzed'' signifies participants evaluable for this outcome measure.

Cmax of midazolam was reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=13 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 5: Maximum Observed Concentration (Cmax) of Midazolam	—	33.71 Nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 34	30.20 Nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 28	—	—	—	—	—

PRIMARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number of Participants Analyzed'' signifies participants evaluable for this outcome measure.

AUCinf of midazolam was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=13 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 5: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of Midazolam	—	94.30 NanogramHour per milliliter (nghr/mL) Geometric Coefficient of Variation 26	79.85 NanogramHour per milliliter (nghr/mL) Geometric Coefficient of Variation 31	—	—	—	—	—

PRIMARY outcome

Timeframe: From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 52 days)

Population: Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.

An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=23 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=23 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=24 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 6: Number of Participants With TEAEs	—	4 Participants	6 Participants	4 Participants	—	—	—	—

PRIMARY outcome

Timeframe: From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 52 days)

Population: Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

Laboratory parameters included: hematology (lymphocytes \<0.6\*LLN \[10\^3/mm3\], lymphocytes/leukocytes \>1.2\*ULN \[%\], neutrophils \<0.8\*LLN \[10\^3/mm3\], neutrophils/leukocytes \<0.8\*LLN \[%\], basophils/leukocytes \>1.2\*ULN \[%\], eosinophils/leukocytes \>1.2\*ULN \[%\], monocytes/leukocytes \>1.2\*ULN \[%\], partial thromboplastin time \>1.1\*ULN \[seconds\], prothrombin time \>1.1\*ULN \[seconds\]), chemistry (bicarbonate \<0.9\*LLN \[mEq/L\], creatine kinase \> 2.0\*ULN \[U/L\], lipase \> 1.5\*ULN \[U/L\], urobilinogen \>=1 \[ehrlich units/deciliter\] {EU/dL}) and urinalysis (urine hemoglobin \>=1, leukocyte esterase \>=1, ketones \>=1, bacteria \>20 \[per low power field\] {/lpf}). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=23 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=22 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=24 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 6: Number of Participants With Laboratory Test Abnormalities	—	12 Participants	12 Participants	7 Participants	—	—	—	—

PRIMARY outcome

Timeframe: Up to Day 6 of each period

Population: Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.

Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 bpm, value \> 120 bpm.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=23 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=23 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=24 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 6: Number of Participants With Vital Signs Meeting Pre-Defined Criteria SBP value < 90 mmHg	—	1 Participants	2 Participants	3 Participants	—	—	—	—
Part 6: Number of Participants With Vital Signs Meeting Pre-Defined Criteria SBP change >= 30 mmHg increase	—	0 Participants	1 Participants	0 Participants	—	—	—	—
Part 6: Number of Participants With Vital Signs Meeting Pre-Defined Criteria SBP change >= 30 mmHg decrease	—	0 Participants	0 Participants	0 Participants	—	—	—	—
Part 6: Number of Participants With Vital Signs Meeting Pre-Defined Criteria DBP value < 50 mmHg	—	0 Participants	0 Participants	0 Participants	—	—	—	—
Part 6: Number of Participants With Vital Signs Meeting Pre-Defined Criteria DBP change >= 20 mmHg increase	—	0 Participants	0 Participants	0 Participants	—	—	—	—
Part 6: Number of Participants With Vital Signs Meeting Pre-Defined Criteria DBP change >= 20 mmHg decrease	—	0 Participants	0 Participants	1 Participants	—	—	—	—
Part 6: Number of Participants With Vital Signs Meeting Pre-Defined Criteria Pulse rate value < 40 bpm	—	0 Participants	0 Participants	0 Participants	—	—	—	—
Part 6: Number of Participants With Vital Signs Meeting Pre-Defined Criteria Pulse rate value > 120 bpm	—	0 Participants	0 Participants	0 Participants	—	—	—	—

PRIMARY outcome

Timeframe: Up to Day 6 of each period

Population: Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.

Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured QTcF interval, aggregate 450 milliseconds (msec) \< value \<= 480 msec and QTcF interval, aggregate 30 msec \< change \<= 60 msec. Number of participants with abnormalities in ECG were reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=23 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=23 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=24 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 6: Number of Participants According to Categorization of ECG Data QTCF interval, aggregate 450 msec < Value <= 480 msec	—	0 Participants	0 Participants	1 Participants	—	—	—	—
Part 6: Number of Participants According to Categorization of ECG Data QTCF interval, aggregate 30 msec < Change <= 60 msec	—	0 Participants	0 Participants	1 Participants	—	—	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported.

Cmax of PF-07817883 was reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 1: Maximum Observed Concentration (Cmax) of PF-07817883	34670 Nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 36	2269 Nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 51	6235 Nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 20	3223 Nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 13	17420 Nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 36	34420 Nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 12	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported.

Tmax of PF-07817883 was reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 1: Time for Cmax (Tmax) of PF-07817883	1.00 Hours Interval 0.55 to 1.5	1.00 Hours Interval 0.5 to 1.5	0.792 Hours Interval 0.5 to 1.5	1.25 Hours Interval 1.0 to 2.0	0.500 Hours Interval 0.5 to 1.0	0.500 Hours Interval 0.5 to 1.05	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported.

AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 1: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883	185700 Nanogram*hour per milliliter Geometric Coefficient of Variation 17	10890 Nanogram*hour per milliliter Geometric Coefficient of Variation 47	34580 Nanogram*hour per milliliter Geometric Coefficient of Variation 25	27080 Nanogram*hour per milliliter Geometric Coefficient of Variation 25	83490 Nanogram*hour per milliliter Geometric Coefficient of Variation 36	160700 Nanogram*hour per milliliter Geometric Coefficient of Variation 33	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported.

Cmax(dn) of PF-07817883 was reported in this outcome measure. Cmax(dn) was calculated as Cmax/dose.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 1: Dose Normalized Cmax (Cmax[dn]) of PF-07817883	8.672 Nanogram per milliliter per milligram Geometric Coefficient of Variation 36	15.14 Nanogram per milliliter per milligram Geometric Coefficient of Variation 51	12.48 Nanogram per milliliter per milligram Geometric Coefficient of Variation 19	6.445 Nanogram per milliliter per milligram Geometric Coefficient of Variation 13	11.61 Nanogram per milliliter per milligram Geometric Coefficient of Variation 36	11.49 Nanogram per milliliter per milligram Geometric Coefficient of Variation 12	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported.

AUClast(dn) of PF-07817883 was reported in this outcome measure. AUClast(dn) was calculated by AUClast/dose.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 1: Dose Normalized AUClast (AUClast[dn]) of PF-07817883	46.43 Nanogram*hour/milliliter/milligram Geometric Coefficient of Variation 17	72.61 Nanogram*hour/milliliter/milligram Geometric Coefficient of Variation 47	69.17 Nanogram*hour/milliliter/milligram Geometric Coefficient of Variation 25	54.16 Nanogram*hour/milliliter/milligram Geometric Coefficient of Variation 25	55.64 Nanogram*hour/milliliter/milligram Geometric Coefficient of Variation 35	53.53 Nanogram*hour/milliliter/milligram Geometric Coefficient of Variation 33	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 1: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883	189400 Nanogramhour/milliliter (nghr/mL) Geometric Coefficient of Variation 19	11250 Nanogramhour/milliliter (nghr/mL) Geometric Coefficient of Variation 53	35950 Nanogramhour/milliliter (nghr/mL) Geometric Coefficient of Variation 25	28120 Nanogramhour/milliliter (nghr/mL) Geometric Coefficient of Variation 28	85320 Nanogramhour/milliliter (nghr/mL) Geometric Coefficient of Variation 34	166100 Nanogramhour/milliliter (nghr/mL) Geometric Coefficient of Variation 34	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

AUCinf(dn) of PF-07817883 was reported in this outcome measure. AUCinf(dn) was calculated as AUCinf/dose.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 1: Dose Normalized AUCinf (AUCinf[dn]) of PF-07817883	47.34 Nanogram*hour/milliliter/milligram Geometric Coefficient of Variation 19	74.99 Nanogram*hour/milliliter/milligram Geometric Coefficient of Variation 53	71.81 Nanogram*hour/milliliter/milligram Geometric Coefficient of Variation 25	56.23 Nanogram*hour/milliliter/milligram Geometric Coefficient of Variation 28	56.86 Nanogram*hour/milliliter/milligram Geometric Coefficient of Variation 34	55.33 Nanogram*hour/milliliter/milligram Geometric Coefficient of Variation 35	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

t1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 1: Terminal Half-Life (t1/2) of PF-07817883	13.05 Hours Standard Deviation 7.3974	4.534 Hours Standard Deviation 0.50659	13.88 Hours Standard Deviation 10.838	15.95 Hours Standard Deviation 8.4657	10.84 Hours Standard Deviation 6.1747	18.79 Hours Standard Deviation 14.234	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCinf\*kel).

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 1: Apparent Volume of Distribution (Vz/F) of PF-07817883	358.7 Liter (L) Geometric Coefficient of Variation 44	86.87 Liter (L) Geometric Coefficient of Variation 48	209.5 Liter (L) Geometric Coefficient of Variation 101	366.1 Liter (L) Geometric Coefficient of Variation 50	242.9 Liter (L) Geometric Coefficient of Variation 80	367.4 Liter (L) Geometric Coefficient of Variation 87	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 1: Apparent Clearance (CL/F) of PF-07817883	21.13 Liter per hour (L/hr) Geometric Coefficient of Variation 19	13.33 Liter per hour (L/hr) Geometric Coefficient of Variation 53	13.93 Liter per hour (L/hr) Geometric Coefficient of Variation 25	17.79 Liter per hour (L/hr) Geometric Coefficient of Variation 28	17.58 Liter per hour (L/hr) Geometric Coefficient of Variation 35	18.09 Liter per hour (L/hr) Geometric Coefficient of Variation 35	—	—

SECONDARY outcome

Timeframe: Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number Analyzed'' signifies participants evaluable at specified timepoints.

Cmax of PF-07817883 was reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=3 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 2: Maximum Observed Concentration (Cmax) of PF-07817883 on Days 1, 5 and 10 Day 1	—	3582 Nanogram/milliliter Geometric Coefficient of Variation 20	8470 Nanogram/milliliter Geometric Coefficient of Variation 39	24100 Nanogram/milliliter Geometric Coefficient of Variation 22	8381 Nanogram/milliliter Geometric Coefficient of Variation 12	—	—	—
Part 2: Maximum Observed Concentration (Cmax) of PF-07817883 on Days 1, 5 and 10 Day 5	—	4234 Nanogram/milliliter Geometric Coefficient of Variation 7	9112 Nanogram/milliliter Geometric Coefficient of Variation 14	27530 Nanogram/milliliter Geometric Coefficient of Variation 22	8260 Nanogram/milliliter Geometric Coefficient of Variation 18	—	—	—
Part 2: Maximum Observed Concentration (Cmax) of PF-07817883 on Days 1, 5 and 10 Day 10	—	3492 Nanogram/milliliter Geometric Coefficient of Variation 15	7852 Nanogram/milliliter Geometric Coefficient of Variation 21	23420 Nanogram/milliliter Geometric Coefficient of Variation 14	7306 Nanogram/milliliter Geometric Coefficient of Variation 25	—	—	—

SECONDARY outcome

Timeframe: Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number Analyzed'' signifies participants evaluable at specified timepoints.

Tmax of PF-07817883 was reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=3 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 2: Time for Cmax (Tmax) of PF-07817883 on Days 1, 5 and 10 Day 1	—	0.759 Hours Interval 0.5 to 1.0	0.775 Hours Interval 0.5 to 1.0	0.500 Hours Interval 0.5 to 1.5	1.00 Hours Interval 1.0 to 1.05	—	—	—
Part 2: Time for Cmax (Tmax) of PF-07817883 on Days 1, 5 and 10 Day 10	—	0.500 Hours Interval 0.5 to 1.0	0.500 Hours Interval 0.5 to 1.0	0.500 Hours Interval 0.5 to 0.5	0.533 Hours Interval 0.5 to 1.0	—	—	—
Part 2: Time for Cmax (Tmax) of PF-07817883 on Days 1, 5 and 10 Day 5	—	0.859 Hours Interval 0.5 to 1.02	0.500 Hours Interval 0.5 to 0.5	0.500 Hours Interval 0.5 to 1.0	0.500 Hours Interval 0.5 to 1.0	—	—	—

SECONDARY outcome

Timeframe: Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number Analyzed'' signifies participants evaluable at specified timepoints.

AUCtau was defined as area under the plasma concentration-time profile from time 0 to time tau, the dosing interval, where tau= 12 hours. AUCtau of PF-07817883 was reported in this outcome measure. AUCtau was calculated by linear/log trapezoidal method.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=3 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 2: Area Under the Plasma Concentration-Time Profile From Time 0 to Time Tau, the Dosing Interval (AUCtau) of PF-07817883 on Days 1, 5 and 10 Day 1	—	14760 Nanogramhour per milliliter (nghr/mL) Geometric Coefficient of Variation 26	36440 Nanogramhour per milliliter (nghr/mL) Geometric Coefficient of Variation 27	108400 Nanogramhour per milliliter (nghr/mL) Geometric Coefficient of Variation 15	36880 Nanogramhour per milliliter (nghr/mL) Geometric Coefficient of Variation 22	—	—	—
Part 2: Area Under the Plasma Concentration-Time Profile From Time 0 to Time Tau, the Dosing Interval (AUCtau) of PF-07817883 on Days 1, 5 and 10 Day 5	—	18460 Nanogramhour per milliliter (nghr/mL) Geometric Coefficient of Variation 15	36300 Nanogramhour per milliliter (nghr/mL) Geometric Coefficient of Variation 10	114000 Nanogramhour per milliliter (nghr/mL) Geometric Coefficient of Variation 22	37680 Nanogramhour per milliliter (nghr/mL) Geometric Coefficient of Variation 29	—	—	—
Part 2: Area Under the Plasma Concentration-Time Profile From Time 0 to Time Tau, the Dosing Interval (AUCtau) of PF-07817883 on Days 1, 5 and 10 Day 10	—	17180 Nanogramhour per milliliter (nghr/mL) Geometric Coefficient of Variation 10	34960 Nanogramhour per milliliter (nghr/mL) Geometric Coefficient of Variation 8	103900 Nanogramhour per milliliter (nghr/mL) Geometric Coefficient of Variation 18	34650 Nanogramhour per milliliter (nghr/mL) Geometric Coefficient of Variation 29	—	—	—

SECONDARY outcome

Timeframe: 12 hours on Day 5 and Day 10

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number Analyzed'' signifies participants evaluable at specified timepoints.

C12 of PF-07817883 was reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=3 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 2: Concentration at 12 Hour Nominal Time Post-Dose (C12) of PF-07817883 on Days 5 and 10 Day 5	—	389.3 Nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 15	734.5 Nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 15	2598 Nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 47	716.0 Nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 47	—	—	—
Part 2: Concentration at 12 Hour Nominal Time Post-Dose (C12) of PF-07817883 on Days 5 and 10 Day 10	—	425.7 Nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 12	865.9 Nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 22	2315 Nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 35	585.5 Nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 28	—	—	—

SECONDARY outcome

Timeframe: Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number Analyzed'' signifies participants evaluable at specified timepoints.

Cmax(dn) of PF-07817883 was reported in this outcome measure. Cmax(dn) was calculated as Cmax/dose.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=3 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 2: Dose Normalized Cmax (Cmax[dn]) of PF-07817883 on Days 1, 5 and 10 Day 1	—	17.93 Nanogram/milliliter/milligram (ng/mL/mg) Geometric Coefficient of Variation 20	14.15 Nanogram/milliliter/milligram (ng/mL/mg) Geometric Coefficient of Variation 39	16.07 Nanogram/milliliter/milligram (ng/mL/mg) Geometric Coefficient of Variation 22	14.00 Nanogram/milliliter/milligram (ng/mL/mg) Geometric Coefficient of Variation 12	—	—	—
Part 2: Dose Normalized Cmax (Cmax[dn]) of PF-07817883 on Days 1, 5 and 10 Day 5	—	21.18 Nanogram/milliliter/milligram (ng/mL/mg) Geometric Coefficient of Variation 7	15.20 Nanogram/milliliter/milligram (ng/mL/mg) Geometric Coefficient of Variation 13	18.35 Nanogram/milliliter/milligram (ng/mL/mg) Geometric Coefficient of Variation 22	13.76 Nanogram/milliliter/milligram (ng/mL/mg) Geometric Coefficient of Variation 18	—	—	—
Part 2: Dose Normalized Cmax (Cmax[dn]) of PF-07817883 on Days 1, 5 and 10 Day 10	—	17.47 Nanogram/milliliter/milligram (ng/mL/mg) Geometric Coefficient of Variation 15	13.07 Nanogram/milliliter/milligram (ng/mL/mg) Geometric Coefficient of Variation 21	15.61 Nanogram/milliliter/milligram (ng/mL/mg) Geometric Coefficient of Variation 14	12.20 Nanogram/milliliter/milligram (ng/mL/mg) Geometric Coefficient of Variation 25	—	—	—

SECONDARY outcome

Timeframe: Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number Analyzed'' signifies participants evaluable at specified timepoints.

AUCtau(dn) was defined as dose normalized AUCtau, where tau= 12 hours. AUCtau(dn) of PF-07817883 was reported in this outcome measure. AUCtau(dn) was calculated as AUCtau/dose.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=3 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 2: Dose Normalized AUCtau (AUCtau[dn]) of PF-07817883 on Days 1, 5 and 10 Day 1	—	73.94 Nanogram*hour/milliliter/milligram Geometric Coefficient of Variation 26	60.70 Nanogram*hour/milliliter/milligram Geometric Coefficient of Variation 27	72.25 Nanogram*hour/milliliter/milligram Geometric Coefficient of Variation 15	61.44 Nanogram*hour/milliliter/milligram Geometric Coefficient of Variation 22	—	—	—
Part 2: Dose Normalized AUCtau (AUCtau[dn]) of PF-07817883 on Days 1, 5 and 10 Day 5	—	92.46 Nanogram*hour/milliliter/milligram Geometric Coefficient of Variation 15	60.49 Nanogram*hour/milliliter/milligram Geometric Coefficient of Variation 10	76.20 Nanogram*hour/milliliter/milligram Geometric Coefficient of Variation 23	62.82 Nanogram*hour/milliliter/milligram Geometric Coefficient of Variation 29	—	—	—
Part 2: Dose Normalized AUCtau (AUCtau[dn]) of PF-07817883 on Days 1, 5 and 10 Day 10	—	86.04 Nanogram*hour/milliliter/milligram Geometric Coefficient of Variation 10	58.28 Nanogram*hour/milliliter/milligram Geometric Coefficient of Variation 8	69.43 Nanogram*hour/milliliter/milligram Geometric Coefficient of Variation 18	57.78 Nanogram*hour/milliliter/milligram Geometric Coefficient of Variation 29	—	—	—

SECONDARY outcome

Timeframe: Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number Analyzed'' signifies participants evaluable at specified timepoints.

Cav of PF-07817883 was reported in this outcome measure. Cav was calculated as AUCtau/12.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=3 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 2: Average Concentration (Cav) of PF-07817883 on Days 5 and 10 Day 5	—	1542 Nanogram/milliliter (ng/mL) Geometric Coefficient of Variation 15	3022 Nanogram/milliliter (ng/mL) Geometric Coefficient of Variation 10	9515 Nanogram/milliliter (ng/mL) Geometric Coefficient of Variation 22	3140 Nanogram/milliliter (ng/mL) Geometric Coefficient of Variation 29	—	—	—
Part 2: Average Concentration (Cav) of PF-07817883 on Days 5 and 10 Day 10	—	1434 Nanogram/milliliter (ng/mL) Geometric Coefficient of Variation 10	2914 Nanogram/milliliter (ng/mL) Geometric Coefficient of Variation 8	8672 Nanogram/milliliter (ng/mL) Geometric Coefficient of Variation 18	2890 Nanogram/milliliter (ng/mL) Geometric Coefficient of Variation 29	—	—	—

SECONDARY outcome

Timeframe: Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number Analyzed'' signifies participants evaluable at specified timepoints.

Rac was defined as observed accumulation ratio for AUCtau, where tau= 12 hours. Rac of PF-07817883 was reported in this outcome measure. Rac was calculated as AUCtau on Day 5 or Day 10/AUCtau on Day 1.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=3 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 2: Observed Accumulation Ratio for AUCtau (Rac) of PF-07817883 on Days 5 and 10 Day 10	—	1.163 Ratio Geometric Coefficient of Variation 18	0.8962 Ratio Geometric Coefficient of Variation 20	0.9605 Ratio Geometric Coefficient of Variation 4	0.9412 Ratio Geometric Coefficient of Variation 8	—	—	—
Part 2: Observed Accumulation Ratio for AUCtau (Rac) of PF-07817883 on Days 5 and 10 Day 5	—	1.250 Ratio Geometric Coefficient of Variation 28	0.9972 Ratio Geometric Coefficient of Variation 18	1.054 Ratio Geometric Coefficient of Variation 9	1.022 Ratio Geometric Coefficient of Variation 7	—	—	—

SECONDARY outcome

Timeframe: Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number Analyzed'' signifies participants evaluable at specified timepoints.

Rac,Cmax of PF-07817883 was reported in this outcome measure. Rac,Cmax was calculated as Cmax on Day 5 or Day 10/Cmax on Day 1.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=3 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 2: Observed Accumulation Ratio for Cmax (Rac,Cmax) of PF-07817883 on Days 5 and 10 Day 5	—	1.183 Ratio Geometric Coefficient of Variation 22	1.075 Ratio Geometric Coefficient of Variation 30	1.142 Ratio Geometric Coefficient of Variation 33	0.9844 Ratio Geometric Coefficient of Variation 18	—	—	—
Part 2: Observed Accumulation Ratio for Cmax (Rac,Cmax) of PF-07817883 on Days 5 and 10 Day 10	—	0.9744 Ratio Geometric Coefficient of Variation 20	0.8471 Ratio Geometric Coefficient of Variation 36	0.9717 Ratio Geometric Coefficient of Variation 18	0.8712 Ratio Geometric Coefficient of Variation 21	—	—	—

SECONDARY outcome

Timeframe: Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number Analyzed'' signifies participants evaluable at specified timepoints.

PTR of PF-07817883 was reported in this outcome measure. PTR was calculated as Cmax/Cmin.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=3 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 2: Peak-to-Trough Ratio (PTR) of PF-07817883 on Days 5 and 10 Day 5	—	10.88 Ratio Geometric Coefficient of Variation 10	13.47 Ratio Geometric Coefficient of Variation 21	10.60 Ratio Geometric Coefficient of Variation 49	13.22 Ratio Geometric Coefficient of Variation 10	—	—	—
Part 2: Peak-to-Trough Ratio (PTR) of PF-07817883 on Days 5 and 10 Day 10	—	8.566 Ratio Geometric Coefficient of Variation 14	11.05 Ratio Geometric Coefficient of Variation 30	10.13 Ratio Geometric Coefficient of Variation 23	12.46 Ratio Geometric Coefficient of Variation 9	—	—	—

SECONDARY outcome

Timeframe: Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number Analyzed'' signifies participants evaluable at specified timepoints.

CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=3 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 2: Apparent Clearance (CL/F) of PF-07817883 on Days 5 and 10 Day 5	—	10.83 Liter/hour (L/hr) Geometric Coefficient of Variation 15	16.57 Liter/hour (L/hr) Geometric Coefficient of Variation 10	13.12 Liter/hour (L/hr) Geometric Coefficient of Variation 22	15.88 Liter/hour (L/hr) Geometric Coefficient of Variation 29	—	—	—
Part 2: Apparent Clearance (CL/F) of PF-07817883 on Days 5 and 10 Day 10	—	11.60 Liter/hour (L/hr) Geometric Coefficient of Variation 10	17.13 Liter/hour (L/hr) Geometric Coefficient of Variation 8	14.37 Liter/hour (L/hr) Geometric Coefficient of Variation 18	17.32 Liter/hour (L/hr) Geometric Coefficient of Variation 29	—	—	—

SECONDARY outcome

Timeframe: Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCtau\*kel).

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=3 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=3 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=3 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 2: Apparent Volume of Distribution (Vz/F) of PF-07817883 on Day 10	—	200.1 Liter Geometric Coefficient of Variation 84	279.6 Liter Geometric Coefficient of Variation 62	198.1 Liter Geometric Coefficient of Variation 98	186.0 Liter Geometric Coefficient of Variation 115	—	—	—

SECONDARY outcome

Timeframe: Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

t1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=3 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=3 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=3 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 2: Terminal Half-Life (t1/2) of PF-07817883 on Day 10	—	13.95 Hours Standard Deviation 9.3938	13.01 Hours Standard Deviation 8.8563	11.44 Hours Standard Deviation 6.8367	8.587 Hours Standard Deviation 5.8524	—	—	—

SECONDARY outcome

Timeframe: Day 10 (0 to 12 hours)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

Aetau was defined as amount excreted in urine as unchanged drug over the dosing interval tau, where tau= 12 hours. Aetau of PF-07817883 was reported in this outcome measure. Aetau was calculated as sum of (urine volume\*urine concentration) for each collection over the dosing interval.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=3 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=3 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 2: Amount Excreted in Urine as Unchanged Drug Over the Dosing Interval Tau (Aetau) of PF-07817883 on Day 10	—	18.47 Milligram (mg) Geometric Coefficient of Variation 16	96.86 Milligram (mg) Geometric Coefficient of Variation 5	373.2 Milligram (mg) Geometric Coefficient of Variation 10	85.85 Milligram (mg) Geometric Coefficient of Variation 20	—	—	—

SECONDARY outcome

Timeframe: Day 10 (0 to 12 hours)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

Aetau% was defined as percentage of dose excreted in urine as unchanged drug over the dosing interval tau, where tau= 12 hours. Aetau% of PF-07817883 was reported in this outcome measure. Aetau% was calculated as 100\*Aetau/dose.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=3 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=3 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 2: Percent of Dose Excreted in Urine as Unchanged Drug Over the Dosing Interval Tau (Aetau%) of PF-07817883 on Day 10	—	9.261 Percentage of Dose Excreted Geometric Coefficient of Variation 16	16.15 Percentage of Dose Excreted Geometric Coefficient of Variation 5	24.90 Percentage of Dose Excreted Geometric Coefficient of Variation 10	14.34 Percentage of Dose Excreted Geometric Coefficient of Variation 20	—	—	—

SECONDARY outcome

Timeframe: Day 10 (0 to 12 hours)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

CLr of PF-07817883 was reported in this outcome measure. CLr was calculated as Aetau/AUCtau.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=3 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=4 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=3 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 2: Renal Clearance (CLr) of PF-07817883 on Day 10	—	1.074 Liter/hour (L/hr) Geometric Coefficient of Variation 20	2.771 Liter/hour (L/hr) Geometric Coefficient of Variation 5	3.586 Liter/hour (L/hr) Geometric Coefficient of Variation 26	2.477 Liter/hour (L/hr) Geometric Coefficient of Variation 51	—	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

Population: Pharmacokinetic (PK) parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number Analyzed'' signifies participants evaluable for the specified rows. This outcome measure was planned to be analyzed only in the tablet formulation as pre-specified in the protocol.

Data for AUClast and AUCinf are reported in the descriptive section. AUClast was calculated by the linear/log trapezoidal method. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis. Ratio based on AUClast and AUCinf of tablet formulations under fed and fasted conditions were reported in statistical analysis.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=12 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 3: Ratio Based on AUClast and AUCinf of Tablet Formulation Under Fed Condition and Fasted Condition AUCinf	—	44140 NanogramHour per milliliter (nghr/mL) Geometric Coefficient of Variation 38	28430 NanogramHour per milliliter (nghr/mL) Geometric Coefficient of Variation 28	42930 NanogramHour per milliliter (nghr/mL) Geometric Coefficient of Variation 43	46170 NanogramHour per milliliter (nghr/mL) Geometric Coefficient of Variation 27	—	—	—
Part 3: Ratio Based on AUClast and AUCinf of Tablet Formulation Under Fed Condition and Fasted Condition AUClast	—	43570 NanogramHour per milliliter (nghr/mL) Geometric Coefficient of Variation 37	27750 NanogramHour per milliliter (nghr/mL) Geometric Coefficient of Variation 29	41620 NanogramHour per milliliter (nghr/mL) Geometric Coefficient of Variation 41	35930 NanogramHour per milliliter (nghr/mL) Geometric Coefficient of Variation 54	—	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. This outcome measure was planned to be analyzed only in the tablet formulation as pre-specified in the protocol.

Data for Cmax are reported in the descriptive section. Ratio based on Cmax of tablet formulation under fed and fasted conditions were reported in statistical analysis.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=12 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 3: Ratio Based on Maximum Observed Concentration (Cmax) of Tablet Formulation Under Fed Condition and Fasted Condition	—	6934 Nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 35	4590 Nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 21	6284 Nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 38	5008 Nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 47	—	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

Population: Pharmacokinetic (PK) parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported.

Tmax of PF-07817883 was reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 3: Time for Cmax (Tmax) of PF-07817883	—	0.750 Hours Interval 0.5 to 1.05	1.01 Hours Interval 0.5 to 2.0	4.00 Hours Interval 1.0 to 4.0	1.34 Hours Interval 1.0 to 2.0	4.00 Hours Interval 2.0 to 6.0	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

Population: Pharmacokinetic (PK) parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported.

Cmax of PF-07817883 was reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 3: Maximum Observed Concentration (Cmax) of PF-07817883	—	9354 Nanogram/milliliter (ng/mL) Geometric Coefficient of Variation 18	6934 Nanogram/milliliter (ng/mL) Geometric Coefficient of Variation 35	4590 Nanogram/milliliter (ng/mL) Geometric Coefficient of Variation 21	6284 Nanogram/milliliter (ng/mL) Geometric Coefficient of Variation 38	5008 Nanogram/milliliter (ng/mL) Geometric Coefficient of Variation 47	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

Population: Pharmacokinetic (PK) parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported.

AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 3: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883	—	42540 Nanogramhour/milliliter (nghr/mL) Geometric Coefficient of Variation 35	43570 Nanogramhour/milliliter (nghr/mL) Geometric Coefficient of Variation 37	27750 Nanogramhour/milliliter (nghr/mL) Geometric Coefficient of Variation 29	41620 Nanogramhour/milliliter (nghr/mL) Geometric Coefficient of Variation 41	35930 Nanogramhour/milliliter (nghr/mL) Geometric Coefficient of Variation 54	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

Population: Pharmacokinetic (PK) parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number of Participants Analyzed'' signifies participants evaluable for this outcome measure.

AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=11 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 3: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883	—	42970 Nanogramhour/milliliter (nghr/mL) Geometric Coefficient of Variation 35	44140 Nanogramhour/milliliter (nghr/mL) Geometric Coefficient of Variation 38	28430 Nanogramhour/milliliter (nghr/mL) Geometric Coefficient of Variation 28	42930 Nanogramhour/milliliter (nghr/mL) Geometric Coefficient of Variation 43	46170 Nanogramhour/milliliter (nghr/mL) Geometric Coefficient of Variation 27	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

Population: Pharmacokinetic (PK) parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number of Participants Analyzed'' signifies participants evaluable for this outcome measure.

t1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=11 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 3: Terminal Half-Life (t1/2) of PF-07817883	—	7.578 Hours Standard Deviation 3.2536	7.957 Hours Standard Deviation 3.8740	10.15 Hours Standard Deviation 2.2890	6.822 Hours Standard Deviation 3.5964	11.07 Hours Standard Deviation 4.4518	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

Population: Pharmacokinetic (PK) parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number of Participants Analyzed'' signifies participants evaluable for this outcome measure.

CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=11 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 3: Apparent Clearance (CL/F) of PF-07817883	—	13.97 Liter/hour Geometric Coefficient of Variation 35	13.58 Liter/hour Geometric Coefficient of Variation 38	21.09 Liter/hour Geometric Coefficient of Variation 28	13.98 Liter/hour Geometric Coefficient of Variation 43	12.98 Liter/hour Geometric Coefficient of Variation 27	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

Population: Pharmacokinetic (PK) parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number of Participants Analyzed'' signifies participants evaluable for this outcome measure.

Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCtau\*kel).

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=11 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=4 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 3: Apparent Volume of Distribution (Vz/F) of PF-07817883	—	136.2 Liter Geometric Coefficient of Variation 55	136.7 Liter Geometric Coefficient of Variation 50	302.2 Liter Geometric Coefficient of Variation 31	120.7 Liter Geometric Coefficient of Variation 55	192.8 Liter Geometric Coefficient of Variation 64	—	—

SECONDARY outcome

Timeframe: From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 49 days)

Population: Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.

An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 3: Number of Participants With TEAEs	—	4 Participants	1 Participants	1 Participants	4 Participants	2 Participants	—	—

SECONDARY outcome

Timeframe: From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 49 days)

Population: Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

Laboratory parameters included: hematology (monocytes/leukocytes \>1.2\*ULN \[%\], partial thromboplastin time \>1.1\*ULN \[seconds\]) and urinalysis (urine hemoglobin \>=1, bacteria \>20 \[/lpf\]). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=2 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 3: Number of Participants With Laboratory Test Abnormalities	—	0 Participants	0 Participants	2 Participants	0 Participants	2 Participants	—	—

SECONDARY outcome

Timeframe: Up to Day 3 of each period

Population: Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.

Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 bpm, value \> 120 bpm. 4. Number of participants with vital signs meeting any of the pre-defined criteria is reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 3: Number of Participants With Vital Signs Meeting Pre-Defined Criteria	—	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—

SECONDARY outcome

Timeframe: Up to Day 3 of each period

Population: Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.

Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed n=6 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 3: Number of Participants With ECG Abnormalities	—	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported.

Tmax of PF-07817883 was reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 4: Time for Cmax (Tmax) of PF-07817883	—	0.500 Hours Interval 0.5 to 2.0	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported.

Cmax of PF-07817883 was reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 4: Maximum Observed Concentration (Cmax) of PF-07817883	—	6791 Nanogram/milliliter (ng/mL) Geometric Coefficient of Variation 35	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported.

AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 4: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883	—	35520 Nanogramhour/milliliter (nghr/mL) Geometric Coefficient of Variation 24	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 4: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883	—	36910 Nanogramhour/milliliter (nghr/mL) Geometric Coefficient of Variation 26	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

t1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 4: Terminal Half-Life (t1/2) of PF-07817883	—	6.882 Hours Standard Deviation 3.0621	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 4: Apparent Clearance (CL/F) of PF-07817883	—	16.26 Liter/hour Geometric Coefficient of Variation 26	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCtau\*kel).

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=5 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 4: Apparent Volume of Distribution (Vz/F) of PF-07817883	—	146.7 Liter Geometric Coefficient of Variation 36	—	—	—	—	—	—

SECONDARY outcome

Timeframe: From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 47 days)

Population: Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.

An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 4: Number of Participants With TEAEs	—	4 Participants	—	—	—	—	—	—

SECONDARY outcome

Timeframe: From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 47 days)

Population: Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.

Laboratory parameters included: hematology (mean corpuscular volume \<0.9\*LLN \[cubic micrometer {um\^3}\], mean corpuscular hemoglobin \<0.9\*LLN \[picograms per cell {pg/cell}\], monocytes/leukocytes \>1.2\*ULN \[%\]). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 4: Number of Participants With Laboratory Test Abnormalities	—	1 Participants	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to Day 11

Population: Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.

Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 bpm, value \> 120 bpm.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 4: Number of Participants With Vital Signs Meeting Pre-Defined Criteria SBP value < 90 mmHg	—	1 Participants	—	—	—	—	—	—
Part 4: Number of Participants With Vital Signs Meeting Pre-Defined Criteria SBP change >= 30 mmHg increase	—	0 Participants	—	—	—	—	—	—
Part 4: Number of Participants With Vital Signs Meeting Pre-Defined Criteria SBP change >= 30 mmHg decrease	—	0 Participants	—	—	—	—	—	—
Part 4: Number of Participants With Vital Signs Meeting Pre-Defined Criteria DBP value < 50 mmHg	—	1 Participants	—	—	—	—	—	—
Part 4: Number of Participants With Vital Signs Meeting Pre-Defined Criteria DBP change >= 20 mmHg increase	—	0 Participants	—	—	—	—	—	—
Part 4: Number of Participants With Vital Signs Meeting Pre-Defined Criteria DBP change >= 20 mmHg decrease	—	0 Participants	—	—	—	—	—	—
Part 4: Number of Participants With Vital Signs Meeting Pre-Defined Criteria Pulse rate value < 40 bpm	—	0 Participants	—	—	—	—	—	—
Part 4: Number of Participants With Vital Signs Meeting Pre-Defined Criteria Pulse rate value > 120 bpm	—	0 Participants	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to Day 11

Population: Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.

Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=6 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 4: Number of Participants With ECG Abnormalities	—	0 Participants	—	—	—	—	—	—

SECONDARY outcome

Timeframe: From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 65 days)

Population: Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.

An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=13 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=13 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 5: Number of Participants With TEAEs	—	11 Participants	10 Participants	—	—	—	—	—

SECONDARY outcome

Timeframe: From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 65 days)

Population: Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

Laboratory parameters included: hematology (lymphocytes \<0.8\*LLN \[10\^3/mm3\], lymphocytes/leukocytes \<0.8\*LLN \[%\], neutrophils/leukocytes \<0.8\*LLN \[%\], monocytes/leukocytes \>1.2\*ULN \[%\]), chemistry (amylase \>1.5\*ULN \[units/liter\] {U/L}), and urinalysis (urine hemoglobin \>=1). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=13 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=7 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 5: Number of Participants With Laboratory Test Abnormalities	—	5 Participants	2 Participants	—	—	—	—	—

SECONDARY outcome

Timeframe: From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 65 days)

Population: Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.

Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 bpm, value \> 120 bpm.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=13 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=13 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 5: Number of Participants With Vital Signs Meeting Pre-Defined Criteria SBP value < 90 mmHg	—	3 Participants	3 Participants	—	—	—	—	—
Part 5: Number of Participants With Vital Signs Meeting Pre-Defined Criteria SBP change >= 30 mmHg increase	—	0 Participants	0 Participants	—	—	—	—	—
Part 5: Number of Participants With Vital Signs Meeting Pre-Defined Criteria SBP change >= 30 mmHg decrease	—	0 Participants	1 Participants	—	—	—	—	—
Part 5: Number of Participants With Vital Signs Meeting Pre-Defined Criteria DBP change >= 20 mmHg increase	—	0 Participants	0 Participants	—	—	—	—	—
Part 5: Number of Participants With Vital Signs Meeting Pre-Defined Criteria DBP change >= 20 mmHg decrease	—	0 Participants	0 Participants	—	—	—	—	—
Part 5: Number of Participants With Vital Signs Meeting Pre-Defined Criteria Pulse rate value < 40 bpm	—	0 Participants	0 Participants	—	—	—	—	—
Part 5: Number of Participants With Vital Signs Meeting Pre-Defined Criteria Pulse rate value > 120 bpm	—	0 Participants	0 Participants	—	—	—	—	—
Part 5: Number of Participants With Vital Signs Meeting Pre-Defined Criteria DBP value < 50 mmHg	—	2 Participants	2 Participants	—	—	—	—	—

SECONDARY outcome

Timeframe: From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 65 days)

Population: Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.

Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=13 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=13 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 5: Number of Participants With ECG Abnormalities	—	0 Participants	0 Participants	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

Tmax of midazolam was reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=13 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 5: Time for Cmax (Tmax) of Midazolam	—	0.500 Hours Interval 0.5 to 1.12	0.500 Hours Interval 0.5 to 1.02	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

AUClast of midazolam was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=13 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 5: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam	—	92.37 Nanogramhour/milliliter (nghr/mL) Geometric Coefficient of Variation 27	77.46 Nanogramhour/milliliter (nghr/mL) Geometric Coefficient of Variation 32	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

t1/2 of midazolam was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=13 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 5: Terminal Half-Life (t1/2) of Midazolam	—	6.589 Hours Standard Deviation 1.6566	6.923 Hours Standard Deviation 1.9185	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

CL/F of midazolam was reported in this outcome measure. CL/F was calculated as dose/AUCinf.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=13 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 5: Apparent Clearance (CL/F) of Midazolam	—	53.02 Liter/hour Geometric Coefficient of Variation 26	62.60 Liter/hour Geometric Coefficient of Variation 31	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.

Vz/F of midazolam was reported in this outcome measure. Vz/F was calculated as dose/(AUCinf\*kel).

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=12 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted n=13 Participants Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 5: Apparent Volume of Distribution (Vz/F) of Midazolam	—	488.5 Liter Geometric Coefficient of Variation 44	598.9 Liter Geometric Coefficient of Variation 45	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. This outcome measure was planned to be analyzed only in the PF-07817883 6000 mg (suspension), fasted arm, as pre-specified in the protocol.

Cmax of PF-07817883 was reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=23 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 6: Maximum Observed Concentration (Cmax) of PF-07817883	—	53160 Nanogram/milliliter (ng/mL) Geometric Coefficient of Variation 21	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. This outcome measure was planned to be analyzed only in the PF-07817883 6000 mg (suspension), fasted arm, as pre-specified in the protocol.

Tmax of PF-07817883 was reported in this outcome measure.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=23 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 6: Time for Cmax (Tmax) of PF-07817883	—	1.00 Hours Interval 0.567 to 1.5	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. This outcome measure was planned to be analyzed only in the PF-07817883 6000 mg (suspension), fasted arm, as pre-specified in the protocol.

AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=23 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 6: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883	—	248300 Nanogramhour/milliliter (nghr/mL) Geometric Coefficient of Variation 17	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. This outcome measure was planned to be analyzed only in the PF-07817883 6000 mg (suspension), fasted arm, as pre-specified in the protocol.

AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.

Outcome measures

Outcome measures
Measure	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 150 mg (Suspension), Fasted n=19 Participants Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 500 mg (Suspension), Fed Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.	PF-07817883 1500 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 3000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.	PF-07817883 4000 mg (Suspension), Fasted Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.
Part 6: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883	—	253000 Nanogramhour/milliliter (nghr/mL) Geometric Coefficient of Variation 17	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)

Population: PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. This outcome measure was planned to be analyzed only in the PF-07817883 6000 mg (suspension), fasted arm, as pre-specified in the protocol.

t1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.